Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 10/20 | 0.44 |
| ▸ | JAK3 | P52333 | 8/20 | 0.43 |
| ▸ | JAK2 | O60674 | 7/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 9/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14494146 | 0.84 | JAK1 (0.44) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL14494151 | 0.84 | JAK1 (0.44) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL14236634 | 0.83 | JAK3 (0.42) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL2630065 | 0.82 | JAK3 (0.41) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL14236482 | 0.81 | JAK3 (0.42) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL2630237 | 0.80 | JAK3 (0.42) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL2630056 | 0.79 | JAK3 (0.41) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL2630054 | 0.79 | JAK3 (0.41) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL10044787 | 0.79 | F2 (0.37) | JAK1JAK3JAK2 | |
| SCHEMBL10044762 | 0.78 | PIM1 (0.43) | JAK1JAK3JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2354139-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354140-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | JAK1 2/4885JAK3 3/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.